Ikarian Capital’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Ikarian Capital’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-86,865	Closed	-$4.83M	–	129
2022 Q2	$4.83M	Hold	86,865	–	–	0.88%	39
2022 Q1	$5.41M	Hold	86,865	–	–	0.71%	40
2021 Q4	$4.86M	Hold	86,865	–	–	0.72%	36
2021 Q3	$4.54M	Sell	86,865 -113,135	-57%	-$6.72M	0.32%	72
2021 Q2	$13.9M	Hold	200,000	–	–	1.12%	22
2021 Q1	$15.5M	Buy	+200,000	New	+$18.4M	0.52%	44

Other funds holding LKFT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Ikarian Capital's LKFT Position: Q3 2022 in Review

Ikarian Capital sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2022, closing a stake of 86,865 shares — an estimated $4.83M sold.

Ikarian Capital first reported a position in LKFT in Q1 2021 and held it in 6 quarters. The position peaked at $15.5M in Q1 2021. 84 funds tracked by Wall St. Rank hold LKFT as of Q3 2022.

Ikarian Capital reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2022 after selling out during the quarter.
Ikarian Capital sold 86,865 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2022, an estimated $4.83M.
Ikarian Capital first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2021 and held it in 6 quarters.
Ikarian Capital's Lakefront Biotherapeutics American Depositary Shares position peaked at $15.5M in Q1 2021.
84 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.